A Phase 2 Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants With Methamphetamine Use Disorder Not Seeking Treatment Receiving a Single Dose of Methamphetamine

The purpose of the study is to evaluate the safety, efficacy, and pharmacokinetics of four single, increasing doses of CS-1103, given by intravenous (IV) infusion in otherwise healthy, non-treatment seeking participants with methamphetamine use disorder in the presence of a clinically relevant dose of methamphetamine HCl (30 mg IV).

Start Date05 Feb 2026

Sponsor / Collaborator

Clear Scientific, Inc.

[+1]

IRCT20250908067186N1

/ RecruitingNot ApplicableIIT

Comparison of the Effectiveness of Electroconvulsive Therapy Plus Pharmacotherapy versus Pharmacotherapy Alone in Treating Methamphetamine-Induced Psychosis

Start Date21 Oct 2025

Sponsor / Collaborator

Zahedan University of Medical Sciences

NCT06989853

/ RecruitingEarly Phase 1IIT

Advancing Troiluzole as a Treatment for Methamphetamine Use Disorder: A Human Laboratory Study

This will be a human laboratory study evaluating the influence of troriluzole treatment on the effects of methamphetamine. Supported by and included in the Helping to End Addiction Long-term® (HEAL) Initiative.

Start Date25 Aug 2025

Sponsor / Collaborator

University of Kentucky

[+1]

100 Clinical Results associated with Methamphetamine Hydrochloride

100 Translational Medicine associated with Methamphetamine Hydrochloride

100 Patents (Medical) associated with Methamphetamine Hydrochloride

15,420

Literatures (Medical) associated with Methamphetamine Hydrochloride

01 Aug 2026·BRAIN BEHAVIOR AND IMMUNITY

Synergistic disruption of the blood-brain barrier in tree shrews by Methamphetamine and HIV-1 Tat via TRPM2-Mediated astrocyte inflammation

Article

Author: Xu, Li-Sha ; Huang, Jian ; Yang, Xue ; Miao, Lin ; Zeng, Xiao-Feng ; Teng, Han-Xin ; Li, Juan ; Zhao, Ying-Jie

Methamphetamine (METH) abuse and HIV infection have emerged as two major public health concerns worldwide. Both METH and the HIV-1 Tat protein (Tat) can enter central nervous system through blood-brain barrier (BBB) and exert neurotoxic effects. However, the specific mechanism underlying their synergistic disruption of BBB remains unclear. Herein, co-culture models of endothelial cells and astrocytes and tree shrews were used to explore the role and mechanism of the Transient receptor potential M2 (TRPM2) in mediating the synergistic BBB damage induced by METH and Tat. In the tree shrew experiment, METH and/or Tat exhibited neurotoxicity, and the combination of them yielded more severe toxic effects characterized by tight junction protein loss, albumin leakage, astrocyte activation, neuroinflammation, and astrocytic TRPM2 activation. Similarly, in vitro experiments revealed that METH and Tat decreased tight junction proteins and transendothelial electrical resistance while increasing the flux of sodium fluorescein, and triggering astrocyte-mediated inflammation and astrocytic TRPM2 activation. However, pharmacological inhibition of TRPM2 mitigated the above-mentioned BBB damage and astrocyte-related inflammation both in vitro and in vivo. Furthermore, inhibition of TRPM2 mitigated METH + Tat-induced stereotypical behavior and anxiety-like behavior in tree shrews. Critically, astrocyte-specific TRPM2 knockdown in tree shrews effectively prevented METH and Tat-induced neuroinflammation and BBB damage, and ameliorated the associated behavioral impairments. This study revealed that METH and Tat could synergistically activate astrocytic TRPM2 channels to induce astrocyte-derived inflammatory response, and ultimately resulted in BBB injury. These findings highlight astrocyte-mediated inflammation as an important mechanism by which METH and Tat synergistically damage the BBB, and the TRPM2 channel represents a promising therapeutic target, providing novel insights into the mechanism of neurotoxicity caused by METH and HIV-1 Tat.

01 Aug 2026·ADDICTIVE BEHAVIORS

Experimental and observational evidence on substance use and metacognition among adults: a systematic review

Review

Author: Babalonis, Shanna ; Ashford, Kristin B ; Seng, Sarret ; Okoli, Chizimuzo T C ; Williams, Lovoria B

PURPOSE:

Metacognition - the capacity to monitor, interpret, and regulate cognitive processes - is essential for adaptive behavioral regulation. Evidence on how substance use relates to metacognitive functioning remains heterogeneous across substances and study designs. This systematic review synthesized evidence examining the relationship between substance use and metacognition among adults.

METHODS:

Following PRISMA 2020 guidelines, we searched PubMed, PsycINFO, CINAHL, and Web of Science from inception through March 2026. Eligible studies included experimental and observational designs enrolling adults (≥18 years) and reporting metacognitive outcomes. Studies not assessing metacognition, involving non-adult samples, or non-empirical publications were excluded. Risk of bias was assessed using Joanna Briggs Institute appraisal tools. Findings were synthesized narratively.

RESULTS:

Thirty-six studies (N = 2,852 participants) were included: randomized controlled trials (n = 16), quasi-experimental (n = 3), cross-sectional (n = 7), and case-control studies (n = 10). Experimental evidence showed substance-specific effects: alcohol findings were mixed across paradigms; cannabinoids generally impaired metacognitive accuracy and calibration; benzodiazepines impaired metacognitive awareness of performance and error detection; methamphetamine demonstrated dose-dependent effects on agency judgments; and nicotine replacement did not restore accuracy following abstinence. Craving states (nicotine, caffeine, methamphetamine) were associated with poorer monitoring and calibration. Observational studies indicated that cocaine, nicotine, opioid, cannabis, alcohol, and polysubstance use were generally associated with poorer metacognitive functioning, including greater maladaptive metacognitive beliefs and reduced monitoring accuracy, though some clinical comparisons showed domain-specific or relatively preserved functioning.

CONCLUSION:

Experimental studies suggest acute substance-related alterations in metacognitive functioning, while observational studies indicate that substance use is generally associated with poorer metacognitive functioning. Greater standardization and longitudinal research are needed to clarify mechanisms and inform interventions.

01 Jul 2026·NEUROPHARMACOLOGY

Disruption of psychostimulant-associated memories by single, low dose ketamine in rats

Article

Author: Modaberi, Shaghayegh ; Anderson, Zada ; Sewell, Christyne M ; Hentges, Shane T ; Ramos, Jonathan D ; Sorg, Barbara A ; Gonzalez, Angela E ; Brown, Travis E

Cocaine and methamphetamine use disorders pose public health concerns due to the high propensity for relapse driven by persistent drug-associated memories. Output from the medial prefrontal cortex (mPFC) regulates relapse and is controlled by parvalbumin (PV) interneurons, which are surrounded by perineuronal nets (PNNs) that support precise PV neuron firing. We previously showed that removal of mPFC PNNs, which reduces PV firing, disrupted reconsolidation of a cocaine self-administration memory when rats were given a novel, but not familiar, memory retrieval session. Ketamine rapidly suppresses PV neuron output, so we tested whether a single low dose (6 mg/kg) administered before or after a familiar or novel memory retrieval session altered cocaine cue reinstatement. Ketamine given prior to the novel, but not familiar, retrieval session reduced cue reinstatement in male Sprague-Dawley rats. In addition, both ketamine treatments combined with a novel retrieval session reduced PNN intensity around PV neurons after cue reinstatement, suggesting that PNN decreases may be unrelated to reinstatement. However, ketamine reduced the number of c-Fos-activated PV neurons immediately after the novel memory retrieval session, indicating that ketamine may reduce reinstatement through reduced PV neuron function at the time of memory retrieval. Ketamine given just prior to a novel memory retrieval session also reduced cue-induced reinstatement in rats trained for methamphetamine, but not fentanyl or sucrose self-administration. Collectively, these studies show that a single, low dose of ketamine combined with a novel memory retrieval reduces psychostimulant-seeking behavior, and may help delineate the mechanisms for ketamine-reduced relapse in psychostimulant use disorders.

News (Medical) associated with Methamphetamine Hydrochloride

01 May 2026

·www.einpresswire.com

Renewal Springs Detox Opens in Oklahoma City to Address Fourth Wave of Opioid Crisis

New medical detox program expands access to safe withdrawal care as fentanyl and meth drive overdose rates across Oklahoma. Detox is no longer a step that can be delayed or done without medical oversight. Renewal Springs exists to provide that level of care when it matters most.” — Tara McDonald OKLAHOMA CITY, OK, UNITED STATES, May 1, 2026 / EINPresswire.com / -- Renewal Springs Detox, a new medical detox center in Oklahoma City, has officially opened its doors with a clear and urgent mission: to help combat Oklahoma’s role in the “fourth wave” of the opioid epidemic, defined by the dangerous co-use of fentanyl and methamphetamine. Across Oklahoma, overdose deaths have surged in recent years, with state data showing that methamphetamine is now involved in a majority of overdose cases, often in combination with synthetic opioids like fentanyl. This shift has created a more complex and volatile addiction landscape, one that requires a higher level of clinical care during the earliest stages of recovery. Renewal Springs Detox was designed to meet that need. The program provides 24/7 medically supervised detox, offering individuals a safe and structured environment to withdraw from alcohol, opioids, benzodiazepines, stimulants, and polysubstance use. With continuous medical monitoring, individualized withdrawal management, and a focus on patient dignity, the facility aims to stabilize clients physically while preparing them for ongoing treatment. “Oklahoma is facing a different kind of addiction crisis than it did even five years ago,” said Executive Director Tara McDonald. “The overlap between meth and fentanyl has raised the stakes. Detox is no longer a step that can be delayed or done without medical oversight. Renewal Springs exists to provide that level of care when it matters most.” The fourth wave of the opioid epidemic has been marked not only by increased overdose risk, but also by more severe withdrawal presentations and higher rates of relapse when individuals do not receive proper stabilization. Many people entering treatment today are managing multiple substances at once, often alongside underlying mental health conditions. Renewal Springs addresses this reality through a clinically grounded approach to drug and alcohol detox in Oklahoma City . Each client receives an individualized detox plan tailored to their substance use history, physical health, and psychological needs. The goal is not to just manage symptoms, but to create a safe entry point into long-term recovery. The program is part of the Pathways Recovery Centers network and operates as a sister program to Country Road Recovery Center, which has provided high-quality addiction treatment services in Oklahoma for the past five years. Together, the programs offer a connected continuum of care, allowing clients to move seamlessly from medical detox in OKC into residential treatment and ongoing recovery support. This continuity is especially critical in the current landscape. Gaps between detox and the next level of care are one of the most common points of relapse. By integrating detox into a broader treatment network, Renewal Springs helps reduce those gaps and improve long-term outcomes. The opening of Renewal Springs represents more than the addition of a new facility. It reflects a broader effort to strengthen addiction treatment in Oklahoma, particularly at a time when the risks associated with substance use have never been higher. “Every person who walks through our doors is taking a significant step,” McDonald added. “Our responsibility is to meet that step with the highest standard of care and to help them move forward into recovery with stability and support.” To learn more about detox services in Oklahoma City at Renewal Springs or to inquire about admission, visit https://www.renewalspringsokc.com . Tara McDonald Renewal Springs +1 405 766-3500 email us here Visit us on social media: LinkedIn Instagram Facebook Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

28 Apr 2026

·www.einpresswire.com

Renew Health Expands Virtual Drug and Alcohol Rehabilitation During New Mexico Behavioral Health Shortage

As provider shortages and rising substance use rates strain the system, telehealth-based treatment offers faster access to care statewide. ROSWELL, NM, UNITED STATES, April 28, 2026 / EINPresswire.com / -- New Mexico continues to face one of the most significant behavioral health workforce shortages in the country, leaving many individuals struggling to access timely addiction and mental health care. At the same time, substance use, particularly involving alcohol, opioids, and methamphetamine, remains a growing concern across the state. In response, Renew Health Addiction Recovery Services is expanding its virtual drug and alcohol rehabilitation programs to help close the gap between need and access. Long wait times, limited provider availability, and geographic barriers have made it difficult for many New Mexicans to begin treatment when they are ready. An estimated 9,000 residents who need medication for substance use disorders are not currently receiving it, underscoring the need for more immediate and flexible treatment options. Renew Health’s expanded telehealth services are designed to reduce obstacles by connecting patients directly with licensed providers through secure, online care. This approach allows individuals to begin treatment quickly, without the added challenges of travel or scheduling limitations. “When someone decides to seek help, timing matters,” said a Renew Health representative. “Delays can mean the difference between starting recovery and continuing to struggle. Expanding virtual drug and alcohol rehabilitation allows us to respond faster and reach communities that have historically been underserved.” Renew Health offers a full spectrum of addiction care , including programs for alcohol use, opioid addiction, methamphetamines, and stimulant use disorders. As overdose risks and withdrawal-related complications remain a concern, Renew Health has also expanded access to medically supervised detox and withdrawal management. These services provide clinical support during the early stages of recovery, helping patients stabilize safely. For individuals who need structured support but cannot step away from daily responsibilities, the organization offers an Intensive Outpatient Program , allowing patients to participate in ongoing therapy and recovery planning while remaining at home. Medication-Assisted Treatment , which combines FDA-approved medications with counseling, also continues to play a central role in improving long-term outcomes. While virtual care is expanding, Renew Health continues to provide in-person services at its clinic locations across the state: Renew Health – Roswell, NM 207 N Union Ave, Roswell, NM 88201 https://renewhealth.com/location/roswell-nm Renew Health – Alamogordo, NM 1900 E 10th St Ste 1, Alamogordo, NM 88310 https://renewhealth.com/location/alamogordo-nm Renew Health – Clovis, NM 809 Parkland Dr #B, Clovis, NM 88101 https://renewhealth.com/location/clovis-nm This hybrid model, combining telehealth with physical clinic access, allows Renew Health to respond more effectively to the current shortage, ensuring patients have consistent care options regardless of location. “We’re not replacing in-person care, we’re expanding it,” the representative added. “The goal is to make treatment available when people need it, in a format that works for their lives. That flexibility is critical right now.” Individuals seeking help can contact Renew Health Addiction Recovery Services at 575-363-HELP, email info@renewhealth.com, or visit https://renewhealth.com to learn more. About Renew Health Addiction Recovery Services: Renew Health Addiction Recovery Services provides accessible, clinically guided care for individuals navigating substance use and behavioral health challenges across New Mexico. By combining telehealth innovation with outpatient support, the organization addresses gaps in care delivery and helps patients begin treatment sooner. Renew Health focuses on practical, ongoing recovery, offering structured support, medical oversight, and individualized care designed to meet the realities of today’s behavioral health landscape. Trent Carter Renew Health +1 575-363-4357 email us here Visit us on social media: Instagram Facebook Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

21 Apr 2026

·www.einpresswire.com

Millennium Health and CDC Collaborate on Clinical Drug Test Dashboard

Offering timely insights on shifting drug use trends to inform targeted, life-saving strategies This is a transformative public-private partnership in service to the public health. We are honored to support CDC efforts to prevent drug overdoses and save lives.” — Millennium Health CEO Scott Walton SAN DIEGO, CA, UNITED STATES, April 21, 2026 / EINPresswire.com / -- Millennium Health announced today that it supplied the clinical urine drug testing (UDT) data underpinning the Centers for Disease Control and Prevention’s new public dashboard on U.S. drug-use trends. This new dashboard uses Millennium Health UDT data to report quarterly and six month, national and regional trends for fentanyl, heroin, cocaine, and methamphetamine use, as well as polysubstance use. This important public health tool is the result of years of collaborative effort between CDC and Millennium Health researchers to understand and optimize UDT data as a surveillance source. “This is a transformative public-private partnership in service to the public health,” said Millennium Health CEO Scott Walton. “We are honored to support CDC efforts to prevent drug overdoses and save lives.” Millennium Health, a leading drug testing company, processes thousands of urine drug tests daily from across the US. Trends in the percentage of specimens testing positive for the reported drugs strongly correlate with trends in fatal drug overdose deaths. “We strive to have the timeliest data about drugs that are driving overdose deaths. These data will have a profound impact on the nation’s ability to provide tailored and rapid interventions, ultimately preventing more overdose deaths,” said Grant Baldwin, PhD, Director of CDC’s Division of Overdose Prevention. In addition to the public release, the CDC will roll out the dashboard to state and local health departments to support local efforts to prevent and address overdose deaths. About Millennium Health Millennium Health is an accredited specialty laboratory with over 15 years of experience in drug testing. We provide objective information about patients’ recent use of prescription medications and/or illicit drugs which helps clinicians monitor and treat millions of Americans living with chronic pain, substance use disorders, mental health disorders or other health conditions. Our ability to monitor drug use trends allows us to alert clinicians, health agencies and others to real-time drug use changes to help inform more targeted drug overdose prevention and response strategies to save lives. Aaron Cohen Millennium Health +1 301-633-6773 PR@millenniumhealth.com Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

100 Deals associated with Methamphetamine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
-	Methamphetamine Hydrochloride	N06BA03	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Attention Deficit Disorder With Hyperactivity	United States	AJENAT PHARMACEUTICALS LLC	31 Dec 1943
Depressive Disorder	Japan	Sumitomo Pharmaceuticals Co., Ltd.	01 Jan 1941
Narcolepsy	Japan	Sumitomo Pharmaceuticals Co., Ltd.	01 Jan 1941
Schizophrenia	Japan	Sumitomo Pharmaceuticals Co., Ltd.	01 Jan 1941

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03825536 (EMRLHD, CTgov)	Phase 4	Methamphetamine dependence \| HIV Infections	14	Placebo oral capsule+Oral Methamphetamine (Oral Methamphetamine, Then Placebo Oral Capsule)	jadekzxkml(hqytroazft) = zgouopqtnt gfnlaejxgy (xzpgyhmrfz, hkauvnyluh - caqmoheuku)	-	08 Apr 2025
				Placebo oral capsule+Oral Methamphetamine (Placebo Oral Capsule, Then Oral Methamphetamine)	jadekzxkml(hqytroazft) = hrcndohamk gfnlaejxgy (xzpgyhmrfz, cnzkhzifxb - sddmomvjuc)
NCT04642820 (DDP, CTgov)	Early Phase 1	-	138	placebo oral tablet+Methamphetamine (Placebo Then Methamphetamine)	lgxlhahqoa(wqrsguualp) = qrdgsjhrhp difpkzsowb (ihfevntnwu, aevchshgzs - ehksyfdgop) View more	-	09 Jan 2025
				placebo oral tablet+Methamphetamine (MethamphetamineThen Placebo)	lgxlhahqoa(wqrsguualp) = hfgqxnpbrj difpkzsowb (ihfevntnwu, wtkvvlfkpj - zrpysmagsz) View more
NCT03790618 (ESP, CTgov)	Phase 1	-	36	3,4-Methylenedioxymethamphetamine+methamphetamine (Placebo)	kfnxfqxzrb(cqqhabqvwn) = lminlzpizf huubecsnuv (fseqppjhfc, 3.22) View more	-	05 Jan 2024
				3,4-Methylenedioxymethamphetamine+methamphetamine (Low Dose MDMA)	kfnxfqxzrb(cqqhabqvwn) = zwnazeqpft huubecsnuv (fseqppjhfc, 3.14) View more
NCT04178993 (CTgov)	Phase 1	Methamphetamine dependence	8	Placebo oral capsule+Methylphenidate+Methamphetamine (Placebo Comparator: Placebo)	jsacmndrqx(owshjtemzt) = iauqedkdlp ptuzokkauc (atgqshsvtb, 0) View more	-	09 Jan 2023
				Placebo oral capsule+Methylphenidate+Duloxetine+Methamphetamine (Active Comparator: Duloxetine)	xobtffnees(xrjkqnamed) = pxkiymjfyp xuootdyqri (stxgaijdsx, 0) View more
NCT02323048 (CAM, CTgov)	Not Applicable	Substance Abuse	90	placebo+methamphetamine (Paired, Low Reward)	fajmihmsih(uavvgtznbe) = hnocehmidx uqtqysuwvt (zgpjunnqqm, pstrnkvcpv - qujwvxeahg) View more	-	26 Jul 2018
				placebo+methamphetamine (Paired, High Reward)	fajmihmsih(uavvgtznbe) = ilwlgmzsxm uqtqysuwvt (zgpjunnqqm, cxerftrblp - gugarqjqmi) View more
NCT01843205 (CTgov)	Phase 1	Methamphetamine abuse \| Methamphetamine dependence	9	Placebo+Methamphetamine (Placebo)	jjplyecgpu(rjjeidouyc) = xmiamtcxqk hydvmxbxtn (aqmuchvezk, 1.25) View more	-	07 Feb 2018
				Placebo+Methamphetamine (Buspirone)	jjplyecgpu(rjjeidouyc) = rqwnjuhrso hydvmxbxtn (aqmuchvezk, 0) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis